LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury

Bibliography

• SCHECHTER NM, WANG ZM, BLACHER RW et al.:Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions. J. Immunol. (1994) 152:4062–4068.
   PubMed Web of Science ®Google Scholar
• COOPERMAN BS, STAVRIDI E, NICKBARG E et al.:Antichymotrypsin interaction with chymotrypsin. Partitioning of the complex. J. Biol. Chem. (1993) 268:23616–23625.
   PubMed Web of Science ®Google Scholar
• JORNVALL H, FISH WW BJORK I: The thrombin cleavagesite in bovine antithrombin. FEBS Lett. (1979) 106:358–362.
   PubMed Web of Science ®Google Scholar
• SCHECHTER NM, SPROWS JL, SCHOENBERGER OL et al: Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. J. Biol. Chem. (1989) 264:21308–21315.
   PubMed Web of Science ®Google Scholar
• RUBIN H, PLOTNICK M, WANG ZM et al.: Reaction of human skin chymotrypsin-like proteinase chymase with plasma proteinase inhibitors. Biochemistry (1994) 33:7627–7633.
   PubMed Web of Science ®Google Scholar
• CARRELL RW, OWENS MC: Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature (1985) 317:730–732.
   PubMed Web of Science ®Google Scholar
• SHIEH B-H, TRAVIS J: The reactive site of human alpha 2-antiplasmin. J. Biol. Chem. (1987) 262:6055–6059.
   PubMed Web of Science ®Google Scholar
• KURDOWSKA A, TRAVIS JJ: Acute phase protein stimula-tion by alpha 1-antichymotrypsin-cathepsin G complexes. Evidence for the involvement of interleukin-6. j Biol. Chem. (1990) 265:21023–21026.
   Google Scholar
• HOFFMAN M, PRATT CW, BROWN RL et al.: Heparin cofactor II-proteinase reaction products exhibit neutrophil chemoattractant activity. Blood (1989) 73:1682–1685.
   PubMed Web of Science ®Google Scholar
• BANDA MJ, RICE AG, GRIFFIN GL et al.: Alpha 1-proteinase inhibitor is a neutrophil chemoattractant after proteolytic inactivation by macrophage elastase. Biol Chem. (1988) 263:4481–4484.
   Web of Science ®Google Scholar
• BANDA MJ, RICE AG, GRIFFIN GL et al.: The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattrac-tant../. Exptl. Med. (1988) 167:1608–1615.
   Google Scholar
• POTEMPA J, FEDAK D, DUBIN A eta].: Proteolytic inacti-vation of alpha-1-anti-chymotrypsin. Sites of cleavage and generation of chemotactic activity. J. Biol. Chem. (1991) 266:21482–21487.
   Google Scholar
• MAST AE, ENGHILD JJ, NAGASE H et al.: Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). J. Biol. Chem. (1991) 266:15810–15816.
   PubMed Web of Science ®Google Scholar
• MAST AE, ENGHILD JJ, PIZZO SV et al: Analysis of theplasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensino-gen, and ovalbumin. Biochemistry (1991) 30: 1723-1730.
   Google Scholar
• PIZZO SV, MAST AE, FELDMAN SR, SALVESEN G: In vivocatabolism of alpha 1-antichymotrypsin is mediated by the Serpin receptor which binds alpha 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim. Biophys. Acta (1988) 967:158–162.
   PubMed Web of Science ®Google Scholar
• SCHUSTER MG, ENRIQUEZ PM, CURRAN P, COOPERMANBS, RUBIN H: Regulation of neutrophil superoxide by antichymotrypsin-chymotrypsin complexes. J. Biol. Chem. (1992) 267:5056–5059.
   PubMed Web of Science ®Google Scholar
• BUCURENCI N, BLAKE DR, CHIDWICK K et al: Inhibitionof neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBSLett. (1992) 300:21–24.
   PubMed Web of Science ®Google Scholar
• HARLAN JM: Leukocyte-endothelial interactions. Blood(1985) 65:513–525.
   PubMed Web of Science ®Google Scholar
• CARLOS TM, HARLAN JM: Leukocyte-endothelialadhesion molecules. Blood (1994) 84:2068–2101.
   PubMed Web of Science ®Google Scholar
• HARLAN JM, WINN RK, VEDDER NB et al.: In: Adhesion: ItsRole in Inflammatory Diseases. JM Harlan, DY Lui (Eds.), WH Freeman Co. New York (1992):117.
   Google Scholar
• BEVILACQUA MP, NELSON RM, MONNORI G et al.: Endothelial-leukocyte adhesion molecules in human disease. Ann. Rev. Med. (1994) 45:361–378.
   PubMed Web of Science ®Google Scholar
• REMOLD-O'DONNELL E, PARENT D: Two proteolytic pathways for down-regulation of the barrier molecule CD43 of human neutrophils. J. ImmunoL (1994) 152:3595–3605.
   Google Scholar
• NATHAN C, XIE Q, HALBWACH-MECARELLI L et al.:Albumin inhibits neutrophil spreading and hydrogen peroxide release by blocking the shedding of CD43 (sialophorin, leukosialin). J. Cell Biol. (1993) 122:243–256.
   PubMed Web of Science ®Google Scholar
• REMOLD-O'DONNELL E, PARENT D: Downregulation ofneutrophil CD43 by opsonized zymosan. Blood (1995) 85:337–342.
   Google Scholar
• HARTSHORN KL, LIOU LS, WHITE MR et al.: Neutrophildeactivation by influenza A virus. Role of hemagglu-tinin binding to specific sialic acid-bearing cellular proteins. J. Immunol (1995) 154:3952–3960.
   Google Scholar
• KOCHANEK PM HALLENBECK JM: Polymorphonuclearleukocytes and monocytes/macrophages in the pathogenesis of cerebralischemia and stroke. Stroke (1992) 23:1367–1379.
   PubMed Web of Science ®Google Scholar
• SANDS H, LI J, DUGGARAJU R, KOLAN HR et al.: Biodistri- bution and pharmacokinetics of 131I-labeled LEX032, a recombinant hybrid of antichymotrypsin. Drug Metab. Dispost. (1997) 25:631–936.
   PubMed Web of Science ®Google Scholar
• SHIFMAN MA, PIZZO SV: The in vivo metabolism of antithrombin III and antithrombin III complexes. J. Biological Chem. (1982) 257:3243–3248.
   PubMed Web of Science ®Google Scholar
• FUCHS H, MICHALOPOULOS GK, PIZZO SV: Hepatocyte uptake of alpha 1-proteinase inhibitor-trypsin complexes in vitro: evidence for a shared uptake-mechanism for proteinase complexes of alpha 1-proteinase inhibitor and antithrombin III. J. Cell. Biochem. (1984) 25:231–243.
   PubMed Web of Science ®Google Scholar
• TRAVIS J, OWENS M, GEORGE P et al.: Isolation and properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor. J. Biol. Chem. (1985) 260:4384–4389.
   PubMed Web of Science ®Google Scholar
• MAST AE, SALVESEN G, SCHNEBLI HP, PIZZO SV: Evalua-tion of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyeth-ylene glycol conjugates with improved therapeutic potential. J. Lab. Clin. Med. (1990) 116:58–65.
   PubMedGoogle Scholar
• DELYANI JA, MUROHARA T, LEFER AM: Novel recombi-nant serpin, LEX-032, attenuates myocardial reperfu-sion injury in cats. Am. J. Physiol. (Heart Circ. Phyisol 39) (1996):H881 887.
   Google Scholar
• MUROHARA T, GUO J-P, LEFER AM: Cardioprotection bya novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury. J. Pharmacol. Exp. Ther. (1995) 241:1246–1252.
   Google Scholar
• SCALIA R, GAUTHIER TW, LEFER AM: Beneficial effects ofLEX032, a novel recombinant serine protease inhibitor, in murine traumatic shock. Shock (1995) 4:251–256.
   PubMed Web of Science ®Google Scholar
• VON DOBSCHUETZ E, HOFFMANN T, MESSMER K: Inhibition of neutrophil proteinases by the recombi-nant serpin LEX 032 reduces capillary no-reflow in ischemia-reperfusion induced acute pancreatitis. Pharmacol. Exp. Therap. (In Press).
   Google Scholar
• CARNEY DF, JAGES, MA, HUGLI TE, SANDS: Effect ofserine proteinase inhibitors on neutrophilfunction: alpha-1-proteinase inhibitor, antichymotrypsin, and a recombinant hybrid mutant of antichymotrypsin (LEX032) modulate neutrophil adhesion interactions. J. Leukocyte Biol. (1998) 63:75–82.
   PubMed Web of Science ®Google Scholar
• HEISS WD, THIEL A, GROND M et al.: Which targets arerelevant for therapy of acute ischemic stroke? Stroke (1999) 30:1486–1489.
   Google Scholar